scholarly journals The Role of Noncoding RNA in the Pathophysiology and Treatment of Premature Ovarian Insufficiency

2021 ◽  
Vol 22 (17) ◽  
pp. 9336
Author(s):  
Katarzyna Pankiewicz ◽  
Piotr Laudański ◽  
Tadeusz Issat
Keyword(s):  
Neurological Disorders ◽  
Noncoding Rna ◽  
Ovarian Function ◽  
Hormone Replacement ◽  
Premature Ovarian Insufficiency ◽  
Mineral Density ◽  
Ovarian Insufficiency ◽  
Exosomal Mirnas

Premature ovarian insufficiency (POI) is defined as a loss of ovarian function before the age of 40 years, with a prevalence rate estimated at approximately 1%. It causes infertility and is related to serious long-term health consequences, including reduced life expectancy, increased cardiovascular risk, decreased bone mineral density and neurological disorders. There is currently no effective therapy for POI that is widely available in clinical practice; therefore, the treatment of patients with POI is based on hormone replacement therapy. One of the recent advances in the understanding of the pathophysiology of POI has been the role of microRNAs (miRNAs) and other noncoding RNAs (ncRNAs) in the disease. Moreover, intensive research on human folliculogenesis and reproductive biology has led to the development of novel promising therapeutic strategies with the use of exosomal miRNAs derived from mesenchymal stem cells to restore ovarian function in POI patients. This narrative review focuses on the new studies concerning the role of ncRNAs in the pathogenesis of POI, together with their potential as biomarkers of the disease and targets for therapy.

Premature Ovarian Insufficiency and Long-Term Health Consequences

2019 ◽  
Vol 17 (6) ◽  
pp. 604-609 ◽  
Author(s):  
Sophia Tsiligiannis ◽  
Nick Panay ◽  
John C. Stevenson
Keyword(s):  
Ovarian Function ◽  
Management Strategies ◽  
Premature Ovarian Insufficiency ◽  
Health Consequences ◽  
Mineral Density ◽  
Ovarian Insufficiency ◽  
Oestrogen Deficiency ◽  
The Subject ◽  
Neurological Effects

Premature ovarian insufficiency (POI) is defined as the cessation of ovarian function before the age of 40 years. The trio of amenorrhea, elevated gonadotropins and oestrogen deficiency is associated with long-term health consequences including increased cardiovascular disease (CVD), decreased bone mineral density (BMD), significantly reduced fertility, psychological distress, vulvovaginal atrophy, neurological effects and overall reduced life expectancy. There are deficits in our understanding of this condition and subsequently the long-term health consequences. The underlying aetiology of POI and the optimal management strategies are also poorly understood. Our knowledge of long-term cardiovascular consequences specifically relating to women with POI is limited as most data on the subject are derived from studies involving women who experienced menopause at the natural age (after 40 years with an average age of 51).

scholarly journals Long noncoding RNA HCP5 participates in premature ovarian insufficiency by transcriptionally regulating MSH5 and DNA damage repair via YB1

2020 ◽  
Vol 48 (8) ◽  
pp. 4480-4491 ◽  
Author(s):  
Xiaoyan Wang ◽  
Xinyue Zhang ◽  
Yujie Dang ◽  
Duan Li ◽  
Gang Lu ◽  
...  
Keyword(s):  
Dna Damage ◽  
Noncoding Rna ◽  
Dna Damage Repair ◽  
Noncoding Rnas ◽  
Epigenetic Mechanism ◽  
Premature Ovarian Insufficiency ◽  
Genetic Etiology ◽  
Ovarian Insufficiency ◽  
Damage Repair

Abstract The genetic etiology of premature ovarian insufficiency (POI) has been well established to date, however, the role of long noncoding RNAs (lncRNAs) in POI is largely unknown. In this study, we identified a down-expressed lncRNA HCP5 in granulosa cells (GCs) from biochemical POI (bPOI) patients, which impaired DNA damage repair and promoted apoptosis of GCs. Mechanistically, we discovered that HCP5 stabilized the interaction between YB1 and its partner ILF2, which could mediate YB1 transferring into the nucleus of GCs. HCP5 silencing affected the localization of YB1 into nucleus and reduced the binding of YB1 to the promoter of MSH5 gene, thereby diminishing MSH5 expression. Taken together, we identified that the decreased expression of HCP5 in bPOI contributed to dysfunctional GCs by regulating MSH5 transcription and DNA damage repair via the interaction with YB1, providing a novel epigenetic mechanism for POI pathogenesis.

scholarly journals Long-term outcome of ovarian function in women with intermittent premature ovarian insufficiency

2016 ◽  
Vol 86 (2) ◽  
pp. 223-228 ◽  
Author(s):  
Anne Bachelot ◽  
Carole Nicolas ◽  
Maud Bidet ◽  
Jérôme Dulon ◽  
Monique Leban ◽  
...  
Keyword(s):  
Ovarian Function ◽  
Premature Ovarian Insufficiency ◽  
Ovarian Insufficiency ◽  
Term Outcome ◽  
Long Term Outcome

scholarly journals Premature Ovarian Insufficiency - an update on recent advances in understanding and management

F1000Research ◽  
2017 ◽  
Vol 6 ◽  
pp. 2069 ◽  
Author(s):  
Saioa Torrealday ◽  
Pinar Kodaman ◽  
Lubna Pal
Keyword(s):  
Ovarian Function ◽  
Clinical Medicine ◽  
Premature Ovarian Insufficiency ◽  
Clear Understanding ◽  
Timely Manner ◽  
Ovarian Insufficiency ◽  
Ongoing Research ◽  
Health Complications

Premature ovarian insufficiency is a complex and relatively poorly understood entity with a myriad of etiologies and multisystem sequelae that stem from premature deprivation of ovarian sex hormones. Timely diagnosis with a clear understanding of the various comorbidities that can arise from estrogen deficiency is vital to appropriately counsel and treat these patients. Prompt initiation of hormone therapy is critical to control the unsolicited menopausal symptoms that many women experience and to prevent long-term health complications. Despite ongoing efforts at improving our understanding of the mechanisms involved, any advancement in the field in recent decades has been modest at best and researchers remain thwarted by the complexity and heterogeneity of the underpinnings of this entity. In contrast, the practice of clinical medicine has made meaningful strides in providing assurance to the women with premature ovarian insufficiency that their quality of life as well as long-term health can be optimized through timely intervention. Ongoing research is clearly needed to allow pre-emptive identification of the at-risk population and to identify mechanisms that if addressed in a timely manner, can prolong ovarian function and physiology.

scholarly journals Premature ovarian insufficiency – hormone replacement therapy and management of long-term consequences

2018 ◽  
Vol 17 (3) ◽  
pp. 135-138 ◽  
Author(s):  
Paulina Machura ◽  
Monika Grymowicz ◽  
Ewa Rudnicka ◽  
Wojciech Pięta ◽  
Anna Calik-Ksepka ◽  
...  
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Premature Ovarian Insufficiency ◽  
Ovarian Insufficiency ◽  
Long Term Consequences

scholarly journals COMPARISON OF THERAPEUTIC EFFECTS OF DIFFERENT METHODS OF ADMINISTRATION OF MEZENCHIMAL STEM CELLS TO MICE WITH PREMATURE OVARIAN INSUFFICIENCY

2021 ◽  
Vol 76 (2) ◽  
pp. 35-40
Author(s):  
M. I. Kozub ◽  
K. P. Skybina ◽  
I. B. Musatova ◽  
O. V. Prokopiuk ◽  
S. M. Gramatiuk ◽  
...  
Keyword(s):  
Stem Cells ◽  
Sexual Function ◽  
Ovarian Function ◽  
Hormone Replacement ◽  
Morphological Structure ◽  
Premature Ovarian Insufficiency ◽  
Alternative Methods ◽  
Therapeutic Effects ◽  
Ovarian Insufficiency ◽  
Anticancer Chemotherapy

Premature ovarian insufficiency (POI) is condition of female hypogonadism. One of the reasons for the development of POI is anticancer chemotherapy. Currently, hormone replacement therapy is considered the most effective method of treatment POI, which, however, had a number of side effects, requires constant administration of pharmaceuticals, did not restore fertility and correct pathological changes in target organs. Therefore, the search for alternative methods of treatment based on the use of stem cells is promising. The aim of work was to compare the therapeutic effects of different methods of administration of mesenchymal stem cells isolated from adipose tissue (AT MSCs) in restoring sexual function, as well as the behavior of mice with chemotherapy-induced premature ovarian failure. Materials and methods. The investigation was carried out on BALB/c mice with a POI model induced by Cyclophosphamide and Busulfan. A histological examination of preparations of the ovaries and uterus was carried out. We studied the changes in the weight of mice, ovarian function, sexual activity, as well as the behavior of animals in anxiolytic and zoosocial tests after treatment with AT MSCs with intraperitoneal and intraovarian routes of administration. Results and discussion. It was shown that the effectiveness of the use of AT MSCs depends on the method of their administration at the treatment of POI induced by chemotherapy. More rapid and complete restoration of the morphological structure, sexual function, and behavioral responses were observed in mice with POI treated by intraovarial administration of AT MSCs.  

scholarly journals How to Protect Ovarian Function before and during Chemotherapy?

2021 ◽  
Vol 10 (18) ◽  
pp. 4192
Author(s):  
Luca Arecco ◽  
Tommaso Ruelle ◽  
Valentino Martelli ◽  
Andrea Boutros ◽  
Maria Maddalena Latocca ◽  
...  
Keyword(s):  
Ovarian Function ◽  
Premenopausal Women ◽  
Protective Role ◽  
Premature Ovarian Insufficiency ◽  
Negative Consequences ◽  
Key Factors ◽  
Ovarian Insufficiency ◽  
Natural Menopause ◽  
Premenopausal Patients

A significant number of women receive a cancer diagnosis before their age of natural menopause. Among these patients, the most frequent neoplasms are breast cancer, gynecological, and hematological malignancies. Premature ovarian insufficiency and infertility are among the most feared short- to long-term consequences of anticancer treatments in premenopausal patients. Both patient- and treatment-related characteristics are key factors in influencing the risk of gonadotoxicity with the use of chemotherapy. The cryopreservation of oocytes/embryos is a standard strategy for fertility preservations offered to young women interested in future family planning, but it does not allow gonadal function protection during chemotherapy. Ovarian suppression with gonadotropin-releasing hormone agonist (GnRHa) during chemotherapy is now recommended as an option to reduce the risk of gonadotoxicity in order to avoid the negative consequences of premature ovarian insufficiency in premenopausal women receiving cytotoxic therapy, including those not interested in fertility preservation. This review summarizes the risk of treatment-induced gonadotoxicity in premenopausal patients and the evidence available on the protective role of administering GnRHa during chemotherapy to preserve ovarian function.

scholarly journals Premature Ovarian Insufficiency: A Review

2019 ◽  
Author(s):  
Avantika Gupta ◽  
Purnima Tiwari
Keyword(s):  
Ovarian Function ◽  
Well Being ◽  
Premature Ovarian Insufficiency ◽  
Ovarian Insufficiency ◽  
Catastrophic Event ◽  
Timely Initiation ◽  
Population Subgroup ◽  
Short And Long Term

Premature ovarian insufficiency is waning of ovarian function before the age of 40 years. This hypoestrogenic state is characterised by menstrual irregularities and loss of fertility in the patient. This review narrates evaluation, consequences, and management of this complex entity. Truncation in ovarian physiology at such an early age renders the patient prone for various short- and long-term health consequences which negatively affect physical and psychological well-being of the patients. Therefore, this review emphasises that timely initiation of hormonal therapy is mandatory to mitigate the distressing menopausal and/or other hypoestrogenic symptoms to improve the quality of life of such patients. Although much has been said about premature ovarian insufficiency, many aspects of this condition still need to be explored in order to identify this population subgroup before happening of the catastrophic event and to formulate strategies and interventions to delay the premature cessation of ovarian functions.

scholarly journals The Role of Gene Therapy in Premature Ovarian Insufficiency Management

Biomedicines ◽  
2018 ◽  
Vol 6 (4) ◽  
pp. 102 ◽  
Author(s):  
Ihor Atabiekov ◽  
Elie Hobeika ◽  
Ujalla Sheikh ◽  
Abdeljabar El Andaloussi ◽  
Ayman Al-Hendy
Keyword(s):  
Gene Therapy ◽  
Genetic Disorders ◽  
Hormone Replacement ◽  
Follicle Stimulating Hormone ◽  
Premature Ovarian Insufficiency ◽  
Ovarian Insufficiency ◽  
Future Directions ◽  
Reproductive Techniques ◽  
Anticancer Treatment

Premature ovarian insufficiency (POI) is a highly prevalent disorder, characterized by the development of menopause before the age of 40. Most cases are idiopathic; however, in some women the cause of this condition (e.g.; anticancer treatment, genetic disorders, and enzymatic defects) could be identified. Although hormone-replacement therapy, the principal therapeutic approach for POI, helps alleviate the related symptoms, this does not effectively solve the issue of fertility. Assisted reproductive techniques also lack efficacy in these women. Thus, an effective approach to manage patients with POI is highly warranted. Several mechanisms associated with POI have been identified, including the lack of function of the follicle-stimulating hormone (FSH) receptor, alterations in apoptosis control, mutations in Sal-like 4 genes, and thymulin or basonuclin-1 deficiency. The above mentioned may be good targets for gene therapy in order to correct defects leading to POI. The goal of this review is to summarize current experiences on POI studies that employed gene therapy, and to discuss possible future directions in this field.

scholarly journals CLINICAL PROFILE OF WOMEN WITH PREMATURE OVARIAN INSUFFICIENCY ATTENDING A TERTIARY CARE CENTER: A CROSS SECTIONAL STUDY

2020 ◽  
pp. 1-2
Author(s):  
Anupama Bahadur ◽  
Rajlaxmi Mundhra ◽  
Aditi Jindal ◽  
Latika Chawla ◽  
Kavita Khoiwal ◽  
...  
Keyword(s):  
Ovarian Function ◽  
Medical Condition ◽  
Care Center ◽  
Hormone Replacement ◽  
Tertiary Care ◽  
Premature Ovarian Insufficiency ◽  
Urban Region ◽  
Ovarian Insufficiency ◽  
Future Fertility ◽  
Study Results

Introduction: Premature ovarian insufficiency (POI) is a depletion of normal ovarian function before age of 40 years accompanied by cessation of menstruation. A couple must be counseled on the effect of POI on future fertility and once diagnosed a woman needs to be evaluated annually. She requires hormone replacement therapy for bone support, cardiovascular and sexual health. Material and methods: A prospective study was conducted in department of Obstetrics and Gynecology at AIIMS Rishikesh from November 2016 to November 2018. We studied the sociodemographic profile, etiology, clinical presentation of 30 patients presenting with POI. Women less than 40 years of age with amenorrhea lasting for four months with two FSH levels in menopausal range (> 40 mIU/ml) obtained atleast one month apart were included in the study. Results: 18 (60%) women presented with amenorrhea between 1 to 2 years. 17 (56.67%) women belonged to urban region and 13 (43.33%) resided in rural area. 22 (73.3%) women had infertility of which 17 (77.27%) had primary infertility and 5 (22.72%) had secondary infertility. For the rest 8 (26.66%) women hypoestrogenic symptom, including vasomotor was the major concern. Conclusion: When POI is diagnosed in adolescent females, patient and her family are often unprepared for such news and its implications are compromised fertility and impaired self-esteem as well as long term hormonal therapy. As clinician we should be mindful of the sensitive nature of this medical condition.

Sign in / Sign up

Export Citation Format

Share Document